A novel Phase II single-arm hybrid design to minimize trial duration and enhance subsequent Phase III trial success rate
{{output}}
Many Phase III trials fail for lack of significant efficacy for the testing agents although their success has been demonstrated in preceding Phase II trials. One of the major reasons for this discordance is the use of different endpoints in Phase II and III tr... ...
